{"id":4286,"company":{"country":"GB","currency":"USD","exchange":"LONDON STOCK EXCHANGE","ipo":"2007-09-21","marketCap":201536,"name":"AstraZeneca PLC","phone":"442073045000","outstanding":1550.280029296875,"symbol":"AZN","website":"https://www.astrazeneca.com/","industry":"Pharmaceuticals"},"price":85.215,"year":2024,"month":8,"day":22,"weekday":"Thursday","title":"Historical Performance of AstraZeneca PLC Stock Compared to Industry Benchmarks","date":"2024-08-22","url":"/posts/2024/08/22/AZN","content":[{"section":"Introduction","text":"AstraZeneca PLC is a multinational pharmaceutical company that specializes in the research, development, and commercialization of prescription drugs. To analyze the historical performance of AstraZeneca PLC stock, we will compare it to industry benchmarks, which often include indices representing the pharmaceutical or healthcare sectors."},{"section":"Stock Performance","text":"Historical data shows that AstraZeneca PLC's stock has experienced fluctuations over the years, influenced by various factors such as drug approvals, clinical trial results, and macroeconomic conditions. It is essential to analyze the stock's performance in comparison to industry benchmarks to gain a comprehensive understanding."},{"section":"Comparison to Industry Benchmarks","text":"To maintain objectivity, we will consider commonly used industry benchmarks such as the S\u0026P 500 Pharmaceutical Index and other relevant indices. By comparing AstraZeneca PLC's stock performance to these benchmarks, we can assess its relative performance within the pharmaceutical sector."},{"section":"Key Metrics","text":"Key metrics that can be analyzed include stock price performance over different time periods (e.g., 1 year, 5 years, or 10 years), market capitalization, dividend yield, price-to-earnings ratio (P/E ratio), and earnings per share (EPS). These metrics provide insights into the stock's growth, valuation, and profitability."},{"section":"Trends and Observations","text":"After analyzing the historical performance of AstraZeneca PLC stock compared to industry benchmarks, trends and observations may emerge. For example, it may reveal whether the stock consistently outperforms or underperforms the benchmark over various time periods or if it exhibits higher volatility."},{"section":"External Factors","text":"It is important to consider external factors that may have influenced the stock's performance. These could include regulatory changes, mergers and acquisitions, clinical trial outcomes, patent expirations, or competitive landscape shifts. Understanding these factors is crucial to interpreting the stock's historic performance accurately."},{"section":"Investment Implications","text":"Based on the historical performance analysis, investors can make informed decisions regarding AstraZeneca PLC stock. By comparing its performance to industry benchmarks, evaluating key metrics and considering external factors, investors can assess the stock's potential for future growth and determine its suitability within their investment portfolio."},{"section":"Conclusion","text":"Analyzing the historical performance of AstraZeneca PLC stock compared to industry benchmarks provides valuable insights into the stock's relative performance within the pharmaceutical sector. By maintaining objectivity and considering key metrics, trends, and external factors, investors can make informed investment decisions."}],"tags":["LongSignals","Long","Pharmaceuticals"],"news":[{"category":"company","date":1724250600,"headline":"J\u0026J (JNJ) Gets FDA Nod for Chemotherapy-Free Lung Cancer Therapy","id":129482960,"image":"https://media.zenfs.com/en/zacks.com/74bab520128f201c7e6cc3f67385e761","symbol":"AZN","publisher":"Yahoo","summary":"The approval is based on late-stage study data wherein treatment with J\u0026J's (JNJ) Rybrevant plus Lazcluze cut the risk of disease progression or death by 30% in certain NSCLC patients.","url":"https://finance.yahoo.com/news/j-j-jnj-gets-fda-143000172.html"},{"category":"company","date":1724215332,"headline":"Covid-19: vaccine pricing varies wildly by country and company","id":129476391,"image":"https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2021/10/shutterstock_1986496856.jpg","symbol":"AZN","publisher":"Yahoo","summary":"As the vaccine inequity debate rages on, even nations with access to Covid-19 jabs are paying wildly different prices for doses.","url":"https://www.pharmaceutical-technology.com/features/covid-19-vaccine-pricing-varies-country-company/"},{"category":"company","date":1724180400,"headline":"Questor: This pharma giant is set to beat FTSE 100 during bull and bear markets","id":129466139,"image":"https://s.yimg.com/ny/api/res/1.2/HFM0P.U_KMeo02lFH_UuxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD03NTA-/https://media.zenfs.com/en/the_telegraph_818/37a615df165f2f38c60a8f1004c693a5","symbol":"AZN","publisher":"Yahoo","summary":"AstraZeneca has generated a 78pc capital return since we first tipped it as a ‘buy’ in August 2019. This compares with a far more modest 12pc rise in the FTSE 100 index over the same period. And when dividends amounting to 15pc of our notional purchase price are included, the pharmaceutical stock’s total return amounts to 93pc in five years.","url":"https://uk.finance.yahoo.com/news/questor-pharma-giant-set-beat-190000731.html"},{"category":"company","date":1724178602,"headline":"Heard Writers Pick Their Favorite and Least-Favorite Stocks","id":129466709,"image":"https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8","symbol":"AZN","publisher":"Yahoo","summary":"In what is now an August tradition, Heard on the Street’s columnists around the world have begun to publish their stocks picks and pans for the coming year. They will range from household names to companies you might never have heard of.  On Tuesday tech-specialist Dan Gallagher recommended shares of Onsemi.  AstraZeneca, which has a pipeline practically overflowing with cancer therapies, also could give investors a bonus obesity treatment down the road, says David Wainer.","url":"https://finance.yahoo.com/m/559e7cf2-99ec-384a-a811-c2514e98b068/heard-writers-pick-their.html"},{"category":"company","date":1724155800,"headline":"Franklin Equity Income Fund Q2 2024 Commentary","id":129462654,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2095584352/image_2095584352.jpg?io=getty-c-w1536","symbol":"AZN","publisher":"SeekingAlpha","summary":"We continue to have a relatively balanced view of the market overall with optimism that an economic soft landing is likely to occur as inflation moderates.","url":"https://seekingalpha.com/article/4715936-franklin-equity-income-fund-q2-2024-commentary"},{"category":"company","date":1724154780,"headline":"J\u0026J drug combo for lung cancer approved by FDA","id":129465658,"image":"https://www.biopharmadive.com/imgproxy/6JgGj709WMZ18gsPV4CteAPEmoVLeB7XNOXakxp9pkA/g:ce/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL0dldHR5SW1hZ2VzLTE3NDEzMDg1MTguanBn.webp","symbol":"AZN","publisher":"Yahoo","summary":"Approval of Rybrevant and Lazcluze was supported by results from a study that compared the regimen to AstraZeneca’s widely used drug Tagrisso.","url":"https://www.biopharmadive.com/news/johnson-johnson-fda-approval-lazcluze-rybrevant-egfr-lung-cancer/724714/"},{"category":"company","date":1724151600,"headline":"AstraZeneca Is a Cancer Leader. Obesity Could Be a Bonus.","id":129460175,"image":"https://s.yimg.com/ny/api/res/1.2/HPNVGBUfqVvdQLVQKY4Cqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/9df720bf78b92521e6372a45d3a72312","symbol":"AZN","publisher":"Yahoo","summary":"The Anglo-Swedish drugmaker remains one of the best bets in Big Pharma, and potential success in obesity isn’t priced in to the stock.","url":"https://finance.yahoo.com/m/d0dbf46c-4cd2-3774-b903-caea12a3d8ab/astrazeneca-is-a-cancer.html"},{"category":"company","date":1724141520,"headline":"J\u0026J to pay up to USD1.7 billion for heart failure device firm V-Wave","id":129463971,"image":"","symbol":"AZN","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=oiqm03zyqd"},{"category":"company","date":1724126160,"headline":"TOP NEWS: AstraZeneca asthma drug Fasenra gets approval in China","id":129470597,"image":"","symbol":"AZN","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=dnb6c1xvgc"},{"category":"company","date":1724122140,"headline":"LONDON BRIEFING: Gran Tierra makes GBP174 million offer for i3 Energy","id":129463668,"image":"","symbol":"AZN","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=nzyfdoj2x5"},{"category":"company","date":1724116140,"headline":"FTC says FDA biosimilar guidance would increase competition, lead to lower prices","id":129465997,"image":"","symbol":"AZN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3607452009"},{"category":"company","date":1724071200,"headline":"10 Health Care Stocks Whale Activity In Today's Session","id":129445152,"image":"","symbol":"AZN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3606107427"},{"category":"company","date":1724063580,"headline":"Daiichi Sankyo-AstraZeneca’s ENHERTU gains BTD for breast cancer","id":129442033,"image":"https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/08/Daiichi-Sankyo-shutterstock_2249990349-1.jpg","symbol":"AZN","publisher":"Yahoo","summary":"ENHERTU is developed by Daiichi Sankyo and co-commercialised with AstraZeneca.","url":"https://www.pharmaceutical-technology.com/news/daiichi-sankyo-astrazeneca-enhertu/"},{"category":"company","date":1724041860,"headline":"AstraZeneca and Daiichi Sankyo gets US and European nods for Enhertu","id":129448289,"image":"","symbol":"AZN","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=ubvzptdnii"},{"category":"company","date":1724041140,"headline":"AstraZeneca reports EMA validation of Type II Variation application for Enhertu","id":129448290,"image":"","symbol":"AZN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3605691170"},{"category":"company","date":1724041020,"headline":"AstraZeneca announces Enhertu granted breakthrough therapy designation","id":129448291,"image":"","symbol":"AZN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3605690107"},{"category":"company","date":1724032800,"headline":"ENHERTU? Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer","id":129448293,"image":"","symbol":"AZN","publisher":"Business Wire","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=ewo7gvmuw7"},{"category":"company","date":1724032800,"headline":"ENHERTU? Type II Variation Application Validated by EMA for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following At Least One Endocrine Therapy","id":129448292,"image":"","symbol":"AZN","publisher":"Business Wire","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=hkaopn62bs"},{"category":"company","date":1723967340,"headline":"Week In Review: Eisai Enters $1.5 Billion Molecular Glues Pact With SEED","id":129432983,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1635084121/image_1635084121.jpg?io=getty-c-w1536","symbol":"AZN","publisher":"SeekingAlpha","summary":"Japanâs Eisai Pharma formed a collaboration with SEED, a Pennsylvania biotech, to develop molecular glues for targeted protein degradation of disease-causing proteins.","url":"https://seekingalpha.com/article/4715440-week-review-eisai-enters-1-5-billion-molecular-glues-pact-seed"},{"category":"company","date":1723885800,"headline":"Trending stocks this week as U.S. equities notch their best week of 2024","id":129423571,"image":"","symbol":"AZN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3604359393"},{"category":"company","date":1723856820,"headline":"J\u0026J, Roche come out on top in S\u0026P ratings of strongest pharma companies","id":129426936,"image":"","symbol":"AZN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3604498046"},{"category":"company","date":1723828860,"headline":"How Should You Play AstraZeneca (AZN) After Q2 Beat, View Raise?","id":129407131,"image":"https://media.zenfs.com/en/zacks.com/ef77d5a5eb4e72e4dd31ccfaf4ca4ccd","symbol":"AZN","publisher":"Yahoo","summary":"AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge, with several candidates having blockbuster potential.","url":"https://finance.yahoo.com/news/play-astrazeneca-azn-q2-beat-172100950.html"},{"category":"company","date":1723821300,"headline":"FDA Expands AstraZeneca's (AZN) Imfinzi Label in Lung Cancer","id":129407132,"image":"https://media.zenfs.com/en/zacks.com/ef77d5a5eb4e72e4dd31ccfaf4ca4ccd","symbol":"AZN","publisher":"Yahoo","summary":"This approval is based on late-stage study data, which shows that treatment with AstraZeneca's (AZN) Imfinzi reduced the risk of recurrence by 32% in certain non-small cell lung cancer patients.","url":"https://finance.yahoo.com/news/fda-expands-astrazenecas-azn-imfinzi-151500881.html"},{"category":"company","date":1723820632,"headline":"AstraZeneca wins approval for Imfinzi in NSCLC perioperative setting","id":129402600,"image":"https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/08/shutterstock_2476637021-e1723819184658.jpg","symbol":"AZN","publisher":"Yahoo","summary":"The FDA approval of Imfinzi in this indication comes a month after the agency called for an overhaul of perioperative lung cancer trials.","url":"https://www.pharmaceutical-technology.com/news/astrazeneca-wins-approval-for-imfinzi-in-nsclc-perioperative-setting/"},{"category":"company","date":1723818900,"headline":"Pharma Stock Roundup: AZN Gets Approvals for Imfinzi Expanded Use, MRK Inks New Deal","id":129402601,"image":"https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c","symbol":"AZN","publisher":"Yahoo","summary":"Merck (MRK) signs a new collaboration with a private drugmaker. AstraZeneca (AZN) gets approvals for expanded use of Imfinzi.","url":"https://finance.yahoo.com/news/pharma-stock-roundup-azn-gets-143500737.html"},{"category":"company","date":1723812675,"headline":"FDA Approves AstraZeneca's Blockbuster Cancer Drug, Imfinzi, In Combination With Chemo For Non-Small Cell Lung Cancer","id":129400593,"image":"https://media.zenfs.com/en/Benzinga/9059e49dd07e7b38b990769d9cb819f1","symbol":"AZN","publisher":"Yahoo","summary":"Friday, the FDA approved AstraZeneca Plc’s (NASDAQ:AZN) Imfinzi (durvalumab) in combination with chemotherapy for adult patients with resectable early-stage non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements. In this regimen, patients are treated with Imfinzi in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery. The FDA approval was based on the pivotal AEGEAN tri","url":"https://finance.yahoo.com/news/fda-approves-astrazenecas-blockbuster-cancer-125115574.html"},{"category":"company","date":1723806000,"headline":"IMFINZI® (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery","id":129400595,"image":"https://s.yimg.com/ny/api/res/1.2/C1ctcPHyKeLA6MQ2TRhuPg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0zOTY-/https://media.zenfs.com/en/business-wire.com/079c456c6a45c1864106e472c1855c4d","symbol":"AZN","publisher":"Yahoo","summary":"WILMINGTON, Del., August 16, 2024--AstraZeneca’s IMFINZI® (durvalumab) in combination with chemotherapy has been approved in the US for the treatment of adult patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. In this regimen, patients are treated with IMFINZI in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy afte","url":"https://finance.yahoo.com/news/imfinzi-durvalumab-approved-us-treatment-110000445.html"},{"category":"company","date":1723797157,"headline":"AstraZeneca’s sBLA for LS-SCLC treatment gains FDA priority review","id":129397691,"image":"https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/08/AstraZeneca-shutterstock_2394467059.jpg","symbol":"AZN","publisher":"Yahoo","summary":"The application is supported via data from the Phase III ADRIATIC clinical trial in LS-SCLC patients.","url":"https://www.pharmaceutical-technology.com/news/astrazenecas-sbla-imfinzi-gains-fda-priority-review/"},{"category":"company","date":1723791600,"headline":"IMFINZI? (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery","id":129411873,"image":"","symbol":"AZN","publisher":"Business Wire","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=q575npw6db"},{"category":"company","date":1723790640,"headline":"AstraZeneca Imfinzi label expanded in U.S. for lung cancer","id":129411874,"image":"","symbol":"AZN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3602987803"},{"category":"company","date":1723788720,"headline":"AstraZeneca announces approval for Imfinzi combination","id":129411875,"image":"","symbol":"AZN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3602964076"},{"category":"company","date":1723778820,"headline":"AstraZeneca's Infinzi gets US approval for treatment of lung cancer","id":129411876,"image":"","symbol":"AZN","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=8773umr7t5"},{"category":"company","date":1723772460,"headline":"AstraZeneca’s Imfinzi Gains FDA Approval for Lung Cancer","id":129411877,"image":"","symbol":"AZN","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3602790521"},{"category":"company","date":1723757400,"headline":"These 10 drugs will be cheaper after Medicare negotiations","id":129385553,"image":"https://s.yimg.com/ny/api/res/1.2/O8fEjqPSdOwPh7vRGcTY8w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2024-08/3b1e6fb0-5b26-11ef-aeff-2275f1c6f61a","symbol":"AZN","publisher":"Yahoo","summary":"For the first time ever, Medicare has successfully negotiated with pharmaceutical manufacturers to reduce the prices of ten of the most expensive prescription drugs for consumers enrolled in Medicare Part D. These new prices are set to take effect in 2026, offering discounts of nearly 79%. The list of discounted drugs includes Janssen Biotech's Stelara (JNJ), Janssen Pharmaceutical's Xarelto, Bristol Myers Squibb's Eliquis (BMY), Novartis's Entresto (NVS), Pharmacyclics's Imbruvica (ABBV), Merck's Januvia (MRK), Novo Nordisk's Fiasp (NVO), AstraZeneca's Farxiga (AZN), Immunex's Enbrel (AMGN), and Boehringer Ingelheim's Jardiance. Yahoo Finance senior health reporter Anjalee Khemlani breaks down the details. Catch the full interview with Dr. Meena Seshamani, Center for Medicare and Medicaid Services Deputy Administrator and Director of the Center for Medicare, on this topic. For more expert insight and the latest market action, click here to watch this full episode of Wealth! This post was written by Angel Smith","url":"https://finance.yahoo.com/video/10-drugs-cheaper-medicare-negotiations-213000565.html"},{"category":"company","date":1723739688,"headline":"Medicare negotiates lower prices for 10 high-cost drugs","id":129378714,"image":"https://s.yimg.com/ny/api/res/1.2/bafyGSP09vSufyTk_gelHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://s.yimg.com/os/creatr-uploaded-images/2024-08/23c48880-5b18-11ef-8fdf-69e75920f0cc","symbol":"AZN","publisher":"Yahoo","summary":"Medicare has successfully negotiated drug prices with pharmaceutical manufacturers for 10 higher-priced medications. These new prices will take effect in 2026. The drugs include Janssen Biotech's Stelara, Janssen Pharm's Xarelto, Bristol Myers Squibb's (BMY) Eliquis, Novartis' (NVS) Entresto, Pharmacyclics' Imbruvica, Merck's (MRK) Januvia, Novo Nordisk's (NVO) Fiasp, AstraZeneca's (AZN) Farxiga, Immunex's Enbrel, and Boehringer Ingelheim's Jardiance. Dr. Meena Seshamani, Center for Medicare and Medicaid Services Deputy Administrator and Director of the Center for Medicare, joins Yahoo Finance health reporter Anjalee Khemlani to discuss this landmark outcome. Seshamani emphasizes the \"good faith negotiations\" that took place, considering clinical benefits and input from clinical pharmacists to drug pricing experts, all aimed at establishing fair drug pricing for all parties involved. She estimates that the new prices will save the Medicare program $6 billion, with a $1.5 billion in savings for Medicare beneficiaries who pay for prescription drugs. \"Transparency is very important and I think that has been the main goal of standing up this program,\" Seshamani told Yahoo Finance. She highlights the inclusive approach, involving patients, healthcare providers, drug plans, and companies, offering \"multiple opportunities\" for stakeholders to comment on CMS's guidance and negotiate \"access and affordability for the kind of innovative cures and therapies that people need.\" Seshamani concludes, \"I think what you see today with the result of the negotiation program really demonstrates the thoughtful, pragmatic nature that this program has been stood up and that will continue in the future.\" For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Angel Smith","url":"https://finance.yahoo.com/video/medicare-negotiates-lower-prices-10-163448713.html"},{"category":"company","date":1723727196,"headline":"Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations","id":129375103,"image":"https://media.zenfs.com/en/ibd.com/f65b6af95194f103ecd03391cd44e98a","symbol":"AZN","publisher":"Yahoo","summary":"Diabetes treatments from Merck, Novo Nordisk and AstraZeneca will face the steepest cuts under the IRA, a list showed Thursday.","url":"https://finance.yahoo.com/m/e21a0c56-b81b-3868-a3cb-88cfe2b3c315/medicare-slashes-merck%2C-novo%2C.html"},{"category":"company","date":1723733344,"headline":"Big Pharma: The government revealed its list of negotiated drug prices. Here are the reactions.","id":129375968,"image":"https://s.yimg.com/ny/api/res/1.2/o0gHVmPASwuX_QQ8Xa33nQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://s.yimg.com/os/creatr-uploaded-images/2024-08/4f9462e0-5b0a-11ef-bef7-22d12ceda2e8","symbol":"AZN","publisher":"Yahoo","summary":"Medicare drug pricing has been a concern for drugmakers for the past year, as they negotiated with the government. The investor  impact appears to be muted, as Wall Street has not reacted in the hours since the reveal. Others? That's a different story.","url":"https://finance.yahoo.com/news/big-pharma-the-government-revealed-its-list-of-negotiated-drug-prices-here-are-the-reactions-144904457.html"},{"category":"company","date":1723727700,"headline":"Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth?","id":129378717,"image":"https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","symbol":"AZN","publisher":"Yahoo","summary":"Ionis (IONS) enjoys a diverse revenue stream, including numerous sources of collaborative and R\u0026D revenues. These funds enable it to invest in the development of its wholly-owned pipeline.","url":"https://finance.yahoo.com/news/ionis-ions-wholly-owned-drugs-131500752.html"},{"category":"company","date":1723722548,"headline":"Medicare to save $6B in 2026 from the first ever Part D drug pricing negotiations","id":129374870,"image":"https://s.yimg.com/ny/api/res/1.2/Y576aa_LwEyyrA99AV7OjA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04NTg-/https://s.yimg.com/os/creatr-images/2020-01/dd675f90-36a3-11ea-9fb1-e93ee8022e7a","symbol":"AZN","publisher":"Yahoo","summary":"CMS has finally revealed its first set of negotiated prices for 10 prescription drugs that will lower the government's spend on Part D drugs for seniors starting in 2026.","url":"https://finance.yahoo.com/news/medicare-to-save-6b-in-2026-from-the-first-ever-part-d-drug-pricing-negotiations-114908407.html"},{"category":"company","date":1723719600,"headline":"IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US","id":129373823,"image":"https://s.yimg.com/ny/api/res/1.2/Xl7iyf4hq8bCoZ3JLgFDGQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0zOTY-/https://media.zenfs.com/en/business-wire.com/6fc8983025697b9a74f5d8cc4bd1b843","symbol":"AZN","publisher":"Yahoo","summary":"WILMINGTON, Del., August 15, 2024--AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab), based on the results from the positive ADRIATIC Phase III trial in patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based concurrent chemoradiotherapy (cCRT), has been accepted and granted Priority Review in the US.","url":"https://finance.yahoo.com/news/imfinzi-durvalumab-granted-priority-review-110000122.html"},{"category":"company","date":1723718880,"headline":"Healthcare Stocks Rise despite Medicare Price Cuts for Their Drugs","id":129378040,"image":"","symbol":"AZN","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3601819496"},{"category":"company","date":1723717500,"headline":"AstraZeneca (AZN) Imfinzi Combo Gets EU Nod for Uterine Cancer","id":129374877,"image":"https://media.zenfs.com/en/zacks.com/06708d71c63051ca48bf1855727f077b","symbol":"AZN","publisher":"Yahoo","summary":"AstraZeneca's (AZN) Imfinzi plus Lynparza for treating certain patients with primary advanced or recurrent endometrial cancer is approved in the EU based on data from the phase III DUO-E study.","url":"https://finance.yahoo.com/news/astrazeneca-azn-imfinzi-combo-gets-102500309.html"},{"category":"company","date":1723714320,"headline":"Drugs to treat diabetes, heart disease and blood cancers among those affected by price negotiations","id":129384097,"image":"","symbol":"AZN","publisher":"Associated Press, The","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=19sat6c5x0"},{"category":"company","date":1723712220,"headline":"Puma Biotech confirms court ruling on patent dispute with AstraZeneca","id":129376637,"image":"","symbol":"AZN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3601721691"},{"category":"company","date":1723711560,"headline":"Puma Biotech confirms court ruling on patent invalidity, disagrees with verdict","id":129376638,"image":"","symbol":"AZN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3601717232"},{"category":"company","date":1723707960,"headline":"Morning Brew: Alibaba's Mixed Results and Walmart's Strong Performance Highlight Market Activity","id":129377949,"image":"","symbol":"AZN","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3601662407"},{"category":"company","date":1723707420,"headline":"White House says Medicare drug price negotiations will save $6 billion","id":129378046,"image":"","symbol":"AZN","publisher":"United Press International","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=f7bjfg9gwi"},{"category":"company","date":1723705200,"headline":"IMFINZI? (durvalumab) granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US","id":129391621,"image":"","symbol":"AZN","publisher":"Business Wire","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=yog6w01iun"},{"category":"company","date":1723705200,"headline":"Biden administration announces lower prices for 10 Medicare drugs in 2026","id":129378047,"image":"","symbol":"AZN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3601625070"},{"category":"company","date":1723704360,"headline":"U.S. announces final drug prices after Medicare negotiations","id":129378048,"image":"","symbol":"AZN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3601611874"},{"category":"company","date":1723703700,"headline":"U.S. government targets $6B in savings from first Medicare drug price negotiations","id":129378049,"image":"","symbol":"AZN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3601604454"},{"category":"company","date":1723703280,"headline":"U.S. government targets $6B in saving from first Medicare drug price negotiations","id":129378050,"image":"","symbol":"AZN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3601598309"},{"category":"company","date":1723702860,"headline":"AstraZeneca: IMFINZI gets priority review  and BTD to treat LS-SCLC patients","id":129391625,"image":"","symbol":"AZN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3601595963"},{"category":"company","date":1723699320,"headline":"U.S. to announce prices for drugs in Medicare negotiations, NY Times says","id":129378052,"image":"","symbol":"AZN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3601551507"},{"category":"company","date":1723694160,"headline":"TOP NEWS: AstraZeneca's Imfinzi secures US priority review for cancer","id":129391627,"image":"","symbol":"AZN","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=rl92hvm1ns"},{"category":"company","date":1723693903,"headline":"George Soros Amplifies S\u0026P 500 ETF Trust Holdings in Q2 2024","id":129373432,"image":"https://s.yimg.com/ny/api/res/1.2/vc5Ypsh66fVcpeag_Of90A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04NzE-/https://media.zenfs.com/en/us.finance.gurufocus/b5584b42b11504a3650665e750532417","symbol":"AZN","publisher":"Yahoo","summary":"Insight into Soros Fund Management's Latest Strategic Moves","url":"https://finance.yahoo.com/news/george-soros-amplifies-p-500-035143889.html"},{"category":"company","date":1723692840,"headline":"LONDON MARKET OPEN: FTSE 100 green but other stocks suffer on GDP data","id":129391128,"image":"","symbol":"AZN","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=m3tdd7ptkw"},{"category":"company","date":1723690620,"headline":"LONDON BRIEFING: UK economy flat in June partially due to UK election","id":129391129,"image":"","symbol":"AZN","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=w9zo2gn2o3"},{"category":"company","date":1723633800,"headline":"Health Care Roundup: Market Talk","id":129355297,"image":"https://s.yimg.com/ny/api/res/1.2/Qm3wAO6mYFSBJWutNJmnpg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/24d80ea6af1275394adf5ff8dddb3021","symbol":"AZN","publisher":"Yahoo","summary":"0750 GMT –  AstraZeneca  now the first U.K. company to hit the 200 billion-pound valuation target, surpassing Shell and  HSBC  holdings, is poised for continued growth, Shore Capital analyst Sean Conroy says in a market comment.  The Anglo-Swedish pharma giant expects more than 40 pivotal results from clinical trials over the next 18 months that could further propel share momentum, he says.  In May, Chief Executive Officer  Pascal Soriot  said in an interview that becoming the U.K.’s first company valued at 200 billion pounds isn’t the goal but would rather be the outcome of the work.","url":"https://finance.yahoo.com/m/62b9be3e-5561-3bc0-bf1e-650d8eeaa09f/health-care-roundup%3A-market.html"},{"category":"company","date":1723669876,"headline":"Federal Judge Rejects Patent Claims Supporting Puma Biotechnology's Breast Cancer Drug; Company Shares Down After Hours","id":129364649,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"AZN","publisher":"Yahoo","summary":"Federal Judge Rejects Patent Claims Supporting Puma Biotechnology's Breast Cancer Drug; Company Shares Down After Hours","url":"https://finance.yahoo.com/news/federal-judge-rejects-patent-claims-211116499.html"},{"category":"company","date":1723638900,"headline":"Puma Biotech drops after patents ruled invalid in fight with AstraZeneca over Tagrisso","id":129362102,"image":"","symbol":"AZN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3600475284"},{"category":"company","date":1723637640,"headline":"Puma Biotechnology quickly drops after patents for Tagrisso ruled invalid","id":129362105,"image":"","symbol":"AZN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3600453627"},{"category":"company","date":1723630500,"headline":"3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct","id":129458874,"image":"https://media.zenfs.com/en/investorplace_417/5b06085ec403fd81519de4f4d5892664","symbol":"AZN","publisher":"Yahoo","summary":"The outlook for pharmaceutical stocks has been mixed in the last five years. During the pandemic, the early-movers in the vaccine race gained as compared to others. However, sentiments turned significantly negative for the pharmaceutical sector in a post-covid world. I believe that pharmaceutical stocks are poised for a strong comeback in the next 12 to 24 months. There are two major reasons for this view. First, the world faces macroeconomic and geopolitical headwinds. It’s likely that the mark","url":"https://finance.yahoo.com/news/3-pharmaceutical-stocks-surge-higher-101500964.html"},{"category":"company","date":1723630140,"headline":"AstraZeneca's $578M Vaccine Plant In Doubt As UK Government Cuts Funding","id":129364380,"image":"","symbol":"AZN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3600317844"},{"category":"company","date":1723627777,"headline":"AstraZeneca’s new £450m UK vaccine hub under threat from Reeves’ state aid review","id":129350641,"image":"https://www.telegraph.co.uk/content/dam/business/2024/08/14/TELEMMGLPICT000387466329_17236254723910_trans_NvBQzQNjv4BqqVzuuqpFlyLIwiB6NTmJwSX5rhseiWKOo9p9OQ-ymek.jpeg?impolicy=logo-overlay","symbol":"AZN","publisher":"Yahoo","summary":"A multimillion-pound vaccine plant being built by AstraZeneca is under threat amid reports the Treasury could cut the state aid being offered to support it.","url":"https://www.telegraph.co.uk/business/2024/08/14/astrazenecas-450m-vaccine-hub-under-threat-reeves-state-aid/"},{"category":"company","date":1723624200,"headline":"Genprex provides clinical study updates for its Acclaim 1 and 3 trials","id":129362677,"image":"","symbol":"AZN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3600217956"},{"category":"company","date":1723623139,"headline":"China approves AstraZeneca-Daiichi Sankyo’s gastric cancer therapy","id":129349789,"image":"https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/08/AstraZeneca_shutterstock_2482004733.jpg","symbol":"AZN","publisher":"Yahoo","summary":"The conditional approval by the NMPA was influenced by the positive outcomes of the DESTINY-Gastric06 Phase II trial.","url":"https://www.pharmaceutical-technology.com/news/astrazeneca-gastric-cancer-therapy-china/"},{"category":"company","date":1723621146,"headline":"AstraZeneca’s Market Cap Soars Past £200 Billion for First Time","id":129349071,"image":"https://media.zenfs.com/en/bloomberg_markets_842/895a25889b17b9b28a4c71011dfaf763","symbol":"AZN","publisher":"Yahoo","summary":"(Bloomberg) -- AstraZeneca Plc has become the first British company to be valued at more than £200 billion ($257 billion) after a big bet on cancer drugs helped drive a rally in the shares. Most Read from BloombergBiden Invests $100 Million to Fuel Housing ConstructionIn DNC, Chicago’s Embattled Transit System Faces a High-Profile TestJohannesburg Mayor Quits Amid Infighting, Financial WoesHow Chicago’s Gigantic Merchandise Mart Is Still Thriving as Office SpaceGottheimer Calls for Rail Riders t","url":"https://finance.yahoo.com/news/astrazeneca-market-cap-soars-past-073906922.html"},{"category":"company","date":1723619212,"headline":"3 UK Stocks That Are Up To 49.3% Below Intrinsic Value Estimates","id":129349072,"image":"https://media.zenfs.com/en/simply_wall_st__316/da713992716ec87035eff27f58858a3e","symbol":"AZN","publisher":"Yahoo","summary":"The United Kingdom market has recently faced challenges, with the FTSE 100 index closing lower due to weak trade data from China and concerns about global economic recovery. Despite these headwinds, there are opportunities to find undervalued stocks that may offer significant potential for growth. In this article, we will explore three UK stocks that are currently trading up to 49.3% below their intrinsic value estimates.","url":"https://finance.yahoo.com/news/3-uk-stocks-49-3-070652015.html"},{"category":"company","date":1723618260,"headline":"LONDON MARKET MIDDAY: Stocks stay upbeat ahead of US CPI data","id":129364382,"image":"","symbol":"AZN","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=y63ob17yqa"},{"category":"company","date":1723616400,"headline":"AstraZeneca's Imfinzi and Lynparza approved in EU in endometrial cancer patients","id":129364383,"image":"","symbol":"AZN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3600092992"},{"category":"company","date":1723614782,"headline":"AstraZeneca PLC (LON:AZN) Shares Could Be 49% Below Their Intrinsic Value Estimate","id":129349073,"image":"https://media.zenfs.com/en/simply_wall_st__316/bba95900ab96866c17a285be850152bf","symbol":"AZN","publisher":"Yahoo","summary":"Key Insights The projected fair value for AstraZeneca is UK£255 based on 2 Stage Free Cash Flow to Equity AstraZeneca...","url":"https://finance.yahoo.com/news/astrazeneca-plc-lon-azn-shares-055302179.html"},{"category":"company","date":1723614240,"headline":"AstraZeneca Imfinzi/Lynparza combo granted EU approval","id":129364384,"image":"","symbol":"AZN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3600061836"},{"category":"company","date":1723608960,"headline":"TOP NEWS: AstraZeneca celebrates EU approval of Lynparza plus Imfinzi","id":129355150,"image":"","symbol":"AZN","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=unj1btpvbb"},{"category":"company","date":1723606560,"headline":"LONDON MARKET OPEN: Stocks stay green as UK CPI stirs cut speculation","id":129358404,"image":"","symbol":"AZN","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3z8cxq5zd1"},{"category":"company","date":1723604100,"headline":"Invesco Health Care Fund Q2 2024 Review","id":129348664,"image":"","symbol":"AZN","publisher":"SeekingAlpha","summary":"","url":"https://seekingalpha.com/article/4714336-invesco-health-care-fund-q2-2024-review"},{"category":"company","date":1723603920,"headline":"LONDON BRIEFING: UK CPI accelerates for first time since December","id":129358406,"image":"","symbol":"AZN","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=nu14hcpat8"},{"category":"company","date":1723574615,"headline":"Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows","id":129334338,"image":"https://media.zenfs.com/en/Benzinga/382615268894ec5ed3f5d4345583222c","symbol":"AZN","publisher":"Yahoo","summary":"Researchers from the Universities of Cambridge, Bristol, and Edinburgh have revealed that COVID-19 vaccinations may significantly reduce the incidence of arterial thromboses, a leading cause of heart attacks and strokes. The study, published in Nature Communications and supported by the British Heart Foundation Data Science Centre at Health Data Research U.K., analyzed de-identified health records of 46 million adults provided by NHS England. Using health records from 45.7 million adults in Engl","url":"https://finance.yahoo.com/news/struggling-covid-19-vaccines-astrazeneca-184335950.html"},{"category":"company","date":1723570212,"headline":"AstraZeneca becomes Britain’s first £200bn company","id":129333258,"image":"https://s.yimg.com/ny/api/res/1.2/aTtq92YsDYxuhyKH6qsUEw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD03NTA-/https://media.zenfs.com/en/the_telegraph_818/ba4050b0f4e9fbd6bc0d36232cb420e8","symbol":"AZN","publisher":"Yahoo","summary":"AstraZeneca became Britain’s first £200bn company today as investors continued to push up the shares after years of rising revenues and earnings.","url":"https://uk.finance.yahoo.com/news/astrazeneca-becomes-britain-first-200bn-173012470.html"},{"category":"company","date":1723552500,"headline":"Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows","id":129335714,"image":"","symbol":"AZN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3599010323"},{"category":"company","date":1723536420,"headline":"AstraZeneca (AZN) Receives a Sell from UBS","id":129342581,"image":"","symbol":"AZN","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3598700496"},{"category":"company","date":1723531920,"headline":"LONDON MARKET MIDDAY: Stocks turn red as sentiment sours before US PPI","id":129332518,"image":"","symbol":"AZN","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=jczyx6wch8"},{"category":"company","date":1723531080,"headline":"AstraZeneca and Daiichi Sankyo get new approval in China for Enhertu","id":129342614,"image":"","symbol":"AZN","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=gcj0c184mf"},{"category":"company","date":1723510800,"headline":"New European Regulations Could Hinder Rare Disease Treatments, Pharma Industry Raises Concerns Over Stricter Clinical Trial Rules","id":129339655,"image":"","symbol":"AZN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3599041483"},{"category":"company","date":1723460760,"headline":"Texas probes CenterPoint, Starbucks in talks with Elliott: Morning Buzz","id":129312115,"image":"","symbol":"AZN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3597316135"},{"category":"company","date":1723456356,"headline":"Era of ADCs: Pharma companies innovate to stand out in a buzzing market","id":129311160,"image":"https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/08/ADC-image.jpg","symbol":"AZN","publisher":"Yahoo","summary":"As antibody drug conjugate (ADC)-centred deals dominate the oncology space, biotechs are using newer targets and linkers to differentiate themselves.","url":"https://www.pharmaceutical-technology.com/features/era-of-adcs-pharma-companies-innovate-to-stand-out-in-a-buzzing-market/"},{"category":"company","date":1723444500,"headline":"AstraZeneca price target raised by $5 at TD Cowen, here's why","id":129319530,"image":"","symbol":"AZN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3597021036"},{"category":"company","date":1723444320,"headline":"TD Cowen Sticks to Their Buy Rating for AstraZeneca (AZN)","id":129319531,"image":"","symbol":"AZN","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3597018358"},{"category":"company","date":1723439340,"headline":"Big drugmakers focus on smaller deals for biotech companies, WSJ reports","id":129313695,"image":"","symbol":"AZN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3596954253"},{"category":"company","date":1723432740,"headline":"Texas probes CenterPoint, Carlyle weighs Nobian sale: Monday Buzz","id":129317379,"image":"","symbol":"AZN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3597648759"},{"category":"company","date":1723359060,"headline":"Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value","id":129303090,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1335381149/image_1335381149.jpg?io=getty-c-w1536","symbol":"AZN","publisher":"SeekingAlpha","summary":"Ionis Pharmaceuticals has robust pipeline with over 40 drug candidates. Read why I believe IONS is a solid long-term bet despite trading at a slight premium vs peers.","url":"https://seekingalpha.com/article/4713460-ionis-pharmaceuticals-harnessing-rna-targeted-therapies-for-long-term-shareholder-value"},{"category":"company","date":1723317288,"headline":"Why Is AstraZeneca PLC (AZN) a Good Addition to Your Stock Portfolio Now?","id":129293078,"image":"https://s.yimg.com/ny/api/res/1.2/ZxTm_Tzoh0.yFsaiRo6CgA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/9424dea817e4dd53df499193fc019daa","symbol":"AZN","publisher":"Yahoo","summary":"We recently compiled a list of the 10 Best Undervalued UK Stocks To Buy Now. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other undervalued UK stocks. The Economy of the United Kingdom According to a report by KPMG, the economy of the UK is going […]","url":"https://finance.yahoo.com/news/why-astrazeneca-plc-azn-good-191448187.html"},{"category":"company","date":1723182667,"headline":"Apellis: Rare Kidney Disease Data Leads To Possible First To Market","id":129256548,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2162590413/image_2162590413.jpg?io=getty-c-w1536","symbol":"AZN","publisher":"SeekingAlpha","summary":"Positive results from phase 3 study of pegcetacoplan for C3G and IC-MPGN. Re-examination for approval in European markets. Find out why APLS stock is a Buy.","url":"https://seekingalpha.com/article/4712636-apellis-rare-kidney-disease-data-leads-to-possible-first-to-market"},{"category":"company","date":1723163038,"headline":"AstraZeneca PLC (AZN): Should You Invest in This GLP-1 and Weight Loss Stock Right Now?","id":129260202,"image":"https://s.yimg.com/ny/api/res/1.2/ZxTm_Tzoh0.yFsaiRo6CgA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/9424dea817e4dd53df499193fc019daa","symbol":"AZN","publisher":"Yahoo","summary":"We recently compiled a list of the 10 Best GLP-1 and Weight Loss Stocks to Buy Now. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other GLP-1 and weight loss stocks. According to WHO, more than one billion people worldwide are obese, including 650 million adults, […]","url":"https://finance.yahoo.com/news/astrazeneca-plc-azn-invest-glp-002358455.html"},{"category":"company","date":1723134826,"headline":"Conduit acquires three first-in-class assets from AstraZeneca","id":129260204,"image":"https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/08/shutterstock_2483386529-e1723134605199.jpg","symbol":"AZN","publisher":"Yahoo","summary":"Conduit plans to advance two assets, AZD1656 and AZD5658, into Phase II testing for autoimmune disorders.","url":"https://www.pharmaceutical-technology.com/news/conduit-acquires-three-first-in-class-assets-from-astrazeneca/"},{"category":"company","date":1723122300,"headline":"ClearBridge Global Value Improvers Strategy Q2 2024 Commentary","id":129235233,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1365362611/image_1365362611.jpg?io=getty-c-w1536","symbol":"AZN","publisher":"SeekingAlpha","summary":"The ClearBridge Global Value Improvers Strategy outperformed its MSCI World Value Index benchmark during Q2 2024. Click here to read the full fund letter.","url":"https://seekingalpha.com/article/4712217-clearbridge-global-value-improvers-strategy-q2-2024-commentary"},{"category":"company","date":1723121400,"headline":"ClearBridge International Growth ACWI Ex-US Strategy Q2 2024 Commentary","id":129235004,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1028651376/image_1028651376.jpg?io=getty-c-w1536","symbol":"AZN","publisher":"SeekingAlpha","summary":"During Q2 2024, the ClearBridge International Growth ACWI Ex-US Strategy underperformed its Index benchmark. Click here to read the full fund letter.","url":"https://seekingalpha.com/article/4712203-clearbridge-international-growth-acwi-ex-us-strategy-q2-2024-commentary"},{"category":"company","date":1723111200,"headline":"EXCLUSIVE: Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple Assets","id":129232713,"image":"https://media.zenfs.com/en/Benzinga/ff41e5ee2536da73740202f3a736ee64","symbol":"AZN","publisher":"Yahoo","summary":"On Thursday, Conduit Pharmaceuticals Inc. (NASDAQ:CDT) entered into an agreement with AstraZeneca Plc (NASDAQ:AZN) to exclusively license rights to develop AZD1656 and AZD5658, both HK-4 glucokinase activators and AZD5904, a myeloperoxidase inhibitor (MPO). AstraZeneca had progressed AZD1656 and AZD5904 through Phase 1 clinical trials. Conduit initially intends to conduct Phase 2 clinical trials on candidates AZD1656 and AZD5658 in 2024 for applications in autoimmune disorders. Under the terms o","url":"https://finance.yahoo.com/news/exclusive-penny-stock-conduit-pharmaceuticals-100021963.html"},{"category":"company","date":1723110900,"headline":"September 27th Options Now Available For AstraZeneca (AZN)","id":129249987,"image":"","symbol":"AZN","publisher":"Stock Options Channel","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3592068428"},{"category":"company","date":1723101720,"headline":"AstraZeneca licensing deal boosts Conduit Pharma","id":129241574,"image":"","symbol":"AZN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3591830893"},{"category":"company","date":1723098180,"headline":"Conduit Pharmaceuticals signs license agreement with AstraZeneca","id":129241580,"image":"","symbol":"AZN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3591768782"},{"category":"company","date":1723093380,"headline":"EXCLUSIVE: Penny Stock Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple Assets","id":129241582,"image":"","symbol":"AZN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3591706062"}]}